Cohance Lifesciences Q2 Results
- BSE: 543064
- NSE: COHANCE
- ISIN: INE03QK01018
- Sector: Biotechnology & Drugs
BSE
378.15
60.15 (18.92%)
60.15 (18.92%)Volume3.53 M
Updated: Fri 10 Apr, 2026 | 15:40:00
NSE
377.9061.05 (19.27%)
61.05 (19.27%)Volume47.63 M
Updated: Fri 10 Apr, 2026 | 15:40:58
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Cohance Lifesciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 478.64 | 490.54 | -2.43% | 436.19 | 9.73% |
| Depreciation/ Amortization | 44.02 | 45.14 | -2.48% | 37.79 | 16.49% |
| Operating Income | 76.93 | 58.77 | 30.90% | 167.58 | -54.09% |
| Net Income | 74.08 | 48.88 | 51.55% | 138.47 | -46.50% |
| Other Operating Expenses Total | 166.77 | 155.84 | 7.01% | 122.86 | 35.74% |
| Net Income Before Taxes | 83.77 | 62.76 | 33.48% | 174.16 | -51.90% |
| Total Revenue | 555.57 | 549.31 | 1.14% | 603.77 | -7.98% |
| Selling/ General/ Admin Expenses Total | 126.72 | 133.32 | -4.95% | 102.07 | 24.15% |
| Diluted Normalized EPS | 1.93 | 1.43 | 35.38% | 3.61 | -46.54% |